Logo

Fresenius Kabi Discusses the Prospects for the Pegfilgrastim Biosimilar

Share this

Fresenius Kabi Discusses the Prospects for the Pegfilgrastim Biosimilar

Shots:

  • Fresenius Kabi discusses the US FDA’s review about the prospects of pegfilgrastim biosimilar product and the commercialization of the product
  • The company also plans for MSB11456 (biosimilar, tocilizumab) based on the recent positive results which are used for the treatment of RA referencing Actemra
  • The company is awaiting the completion of the US FDA’s inspection to enable the completion of the Stimufend application review. The company has scaled the pegfilgrastim biosimilars in the EU

Ref: Fresenius Kabi | Image: Fresenius Kabi

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions